NASD · Healthcare · Biotechnology · United Kingdom
Immunocore Holdings plc ADR is a small cap company (market value between $300 million and $2 billion) in the Biotechnology industry.
Immunocore Holdings plc is a biotechnology company developing immunomodulating medicines for cancer, infectious diseases, and autoimmune diseases using its ImmTAX platform. The company's lead product KIMMTRAK treats unresectable or metastatic uveal melanoma and is approved across multiple countries with commercial launches underway. Its pipeline includes clinical and pre-clinical programs in oncology, infectious disease, and autoimmune conditions.
From its FY2025 annual report (Form 10-K)
Intrinsic value, DCF valuation, financial health and value investing analysis for the Immunocore Holdings plc ADR stock.
Undervalued: intrinsic value $43.37 per share, market price $30.49, margin of safety 29.7% (as of 2026-10-30).
A 4.2x revenue multiple, discounted for its losses, values the shares at $43.37; the price of $30.49 is 30% below that value.
2 more funds hold it; the full list is part of the paid plan.
12 more in this industry show a wider margin of safety.
IMCR is undervalued (as of the 2026-10-30 close). A 4.2x revenue multiple, discounted for its losses, values the shares at $43.37; the price of $30.49 is 30% below that value.
$43.37 per share (as of the 2026-10-30 close), against a market price of $30.49. That is a margin of safety of 29.7%. The value is the average of the valuation methods that apply to this company, recomputed every night after the US close.